HomeNewsBusinessReal EstateCo-working firm Awfis plans to double office centres to 200 this year
Trending Topics

Co-working firm Awfis plans to double office centres to 200 this year

Several co-working centres may come up in alternative locations such as malls and hotels, as a repurposing of real-estate assets is expected to be a major trend, Awfis founder and CEO Amit Ramani has said

January 19, 2022 / 18:03 IST
Story continues below Advertisement

Homegrown co-working space provider Awfis plans to double to 200 its office centres by adding another 60,000 seats by the end of 2022, founder and CEO Amit Ramani said on January 19.

The concept of a shared workplace is gaining traction as businesses look to cut expenses on office space. The coronavirus outbreak has forced many companies to look at co-working space as employees work from home and the hybrid model of working catches up.

Story continues below Advertisement

“Several malls will be turned into co-working centres going forward. Currently, of the 100 co-working centres in our portfolio, almost 10 percent are in either malls or hotels. Repurposing of assets is the way forward,” he said.

The flexi-workspace provider has opened 100 office centres spread across 4 million sq ft in 14 cities that can seat more than 62,000 people, Ramani said.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show